Skip to main navigation
X4 Pharmaceuticals
  • About
  • our medicine
  • science & pipeline
  • Patients
  • healthcare professionals
  • Investors
    • Company Overview
    • News Releases
    • Events & Presentations
    • Stock Information
    • Analyst Coverage
    • Governance
    • SEC Filings
    • Investor FAQs
  • Careers
X4 Pharmaceuticals X4 Pharmaceuticals
  • About
  • our medicine
  • science & pipeline
  • Patients
  • healthcare professionals
  • Investors
    • Company Overview
    • News Releases
    • Events & Presentations
    • Stock Information
    • Analyst Coverage
    • Governance
    • SEC Filings
    • Investor FAQs
  • Careers

News Releases

May 1, 2024
PDF Version
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 30, 2024
PDF Version
X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024
April 29, 2024
PDF Version
X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome
April 2, 2024
PDF Version
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 1, 2024
PDF Version
X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences
March 21, 2024
PDF Version
X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
March 12, 2024
PDF Version
X4 Pharmaceuticals to Report Fourth-Quarter and Full Year 2023 Financial Results and Host a Conference Call and Webcast on March 21, 2024
March 1, 2024
PDF Version
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 1, 2024
PDF Version
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Pagination

  • First page « first
  • Previous page ‹ previous
  • Page 1
  • Page 2
  • Current page 3
Displaying 21 - 29 of 29

quick links

Quick Links

  • About
  • Patients
  • Investors
  • Careers
footer logo

contact

X4 Pharmaceuticals
61 North Beacon Street
4th Floor
Boston, MA 02134 Phone: 857.529.8300

X4 Pharmaceuticals (Austria) GmbH
Helmut-Qualtinger-Gasse 2
A-103 Vienna, Austria Phone: +43.1.395078300
© 2024 X4 Pharmaceuticals, Inc. All rights reserved.  

Live - Footer

Terms of Use | Privacy | Compliance and Ethics